(R)-(+)-2-(环己烷基甲基)丁二酸 1-甲基酯 | 130165-88-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (R)-(+)-2-(环己烷基甲基)丁二酸 1-甲基酯
• 中文别名: (R)-(+)-2-(环己烷基甲基)丁二酸1-甲基酯
• 英文名称: (R)-2-(Cyclohexylmethyl)-succinic acid 1-methyl ester
• 英文别名: (R)-3-methoxycarbonyl-4-cyclohexylbutyric acid；(R)-2-(Cyclohexylmethyl)succinic acid-1-methyl ester；(3R)-3-(cyclohexylmethyl)-4-methoxy-4-oxobutanoic acid
• CAS: 130165-88-7
• 化学式: C₁₂H₂₀O₄
• mdl: MFCD01311785
• 分子量: 228.288
• InChiKey: TYYNOKUMAOAVBK-SNVBAGLBSA-N

物化性质

• 沸点：
  330.1°C (rough estimate)
• 密度：
  1.1157 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2918990090

SDS

Name:	(R)-2-(Cyclohexylmethyl)Succinic Acid-1-Methyl Ester 95% (98% E.E.) Material Safety Data Sheet
Synonym:	None Known
CAS:	130165-88-7

Section 1 - Chemical Product MSDS Name:(R)-2-(Cyclohexylmethyl)Succinic Acid-1-Methyl Ester 95% (98% E.E.) Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
130165-88-7	(R)-2-(Cyclohexylmethyl)Succinic Acid-	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 130165-88-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H20O4
Molecular Weight: 228.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 130165-88-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(R)-2-(Cyclohexylmethyl)Succinic Acid-1-Methyl Ester - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 130165-88-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 130165-88-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 130165-88-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-(+)-2-(环己烷基甲基)丁二酸 1-甲基酯 在 lithium hydroxide 、 水 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 (R)-2-cyclohexylmethyl-4-morpholin-4-yl-4-oxo-butyric acid
  参考文献：
  名称：

  [EN] INHIBITORS OF CATHEPSIN S
  [FR] INHIBITEURS DE LA CATHEPSINE S

  摘要：

  公开号：

  WO2005034848A3
• 作为产物：
  描述：

  2-Cyclohexylmethylidenesuccinic acid 1-methyl ester 在 [Rh(CLPOX-S)(COD)]BF₄ 氢气 作用下， 以 甲醇 为溶剂， 45.0 ℃ 、500.01 kPa 条件下， 反应 18.0h， 以100%的产率得到(R)-(+)-2-(环己烷基甲基)丁二酸 1-甲基酯
  参考文献：
  名称：

  NOVEL BISPHOSPHINE LIGAND

  摘要：

  提供了一个由以下一般式（I）表示的化合物：【其中R1代表氢原子，或烷基团，R2代表羟基烷基团，或三芳基甲氧基烷基团，或R1和R2结合在一起表示—C(R3)(R4)—（R3和R4代表氢原子，烷基团，或羟基，或R3和R4可以结合在一起表示酮基），或—C(R5)(R6)—O—C(R7)(R8)—（R5到R8代表氢原子，烷基团，或羟基，或R5和R6可以结合在一起表示酮基，R7和R8可以结合在一起表示酮基）；Ar1到Ar4独立地代表芳基（芳基可能具有1到5个相同或不同的取代基），*1到*4表示不对称碳，配置在*1和*2之间为顺式，*3和*4之间为顺式，*2和*3之间为反式】。提供了一种可以轻松合成并给出显示出优越不对称催化剂活性的过渡金属配合物的光学活性膦配体。

  公开号：

  US20080242534A1

文献信息

• Succinate derivative compounds useful as cysteine protease inhibitors
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US06313117B1

  公开（公告）日：2001-11-06

  Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.

  披露了新颖的琥珀酸衍生物化合物，其化学公式为(I)/(Ia): 其中R1, R2, R3, R4, R5, R6, R7, X和A的定义如下。这些化合物作为胱氨酸蛋白酶的抑制剂是有用的。还披露了使用和制造这类化合物的方法。
• Novel succinate derivative compounds useful as cysteine protease inhibitors
  申请人：——

  公开号：US20010041700A1

  公开（公告）日：2001-11-15

  Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1 wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.

  披露了新型琥珀酸衍生物化合物，其化学公式为(I)/(Ia)：1，其中R1、R2、R3、R4、R5、R6、R7、X和A的定义如下。这些化合物可用作胱氨酸蛋白酶的抑制剂。还披露了使用和制造这些化合物的方法。
• Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S
  作者：Arnab K. Chatterjee、Hong Liu、David C. Tully、Jianhua Guo、Robert Epple、Ross Russo、Jennifer Williams、Michael Roberts、Tove Tuntland、Jonathan Chang、Perry Gordon、Thomas Hollenbeck、Christine Tumanut、Jun Li、Jennifer L. Harris

  DOI：10.1016/j.bmcl.2007.02.049

  日期：2007.5

  Peptidic, non-covalent inhibitors of lysosomal cysteine protease cathepsin S (1 and 2) were investigated due to low oral bioavailability, leading to an improved series of peptidomimetic inhibitors. Utilizing phenyl succinamides as the P2 residue increased the oral exposure of this lead series of compounds, while retaining selective inhibition of the cathepsin S isoform. Concurrent investigation of

  由于口服生物利用度低，研究了溶酶体半胱氨酸蛋白酶组织蛋白酶S（1和2）的肽类非共价抑制剂，从而产生了一系列拟肽抑制剂。使用苯基琥珀酰亚胺作为P2残基可增加该先导系列化合物的口腔暴露，同时保留对组织蛋白酶S亚型的选择性抑制作用。对P1和P2亚位点的同时研究导致发现了几种有效的和选择性的组织蛋白酶S抑制剂，这些酶由于消除了饱和脂肪族P2残基而具有良好的药代动力学特性。
• [EN] INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES<br/>[FR] INHIBITEURS DE LA CRUZIPAINE ET AUTRES CYSTEINES PROTEASES
  申请人：INCENTA LTD

  公开号：WO2002057270A1

  公开（公告）日：2002-07-25

  Compounds of general formula (I) or general formula (II) wherein R1, P1, P2, Q, Y, (X)o, (W)n, (V)m, Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds.

  通式(I)或通式(II)的化合物，在规范中定义的R1，P1，P2，Q，Y，(X)o，(W)n，(V)m，Z和U，是cruzipain和其他半胱氨酸蛋白酶抑制剂的抑制剂，并且可用作治疗剂，例如在恶性贫血病中，或用于验证治疗靶点化合物。
• Inhibitors of cathepsin S
  申请人：Liu Hong

  公开号：US20050113356A1

  公开（公告）日：2005-05-26

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了一种选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶时，选择性抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S治疗主体疾病状态的方法。